EUVIMEDEUVIMED entdecken
Vergleichsstudie

Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging

Ji Hye Heo, Da-Eun Sung, Jeonggyu Kang, Xiao-Dong Zhou, Ming-Hua Zheng, Ki-Chul Sung

Nutrition, Metabolism and Cardiovascular Diseases · 2026

DOI: 10.1016/j.numecd.2026.104817 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026. Verfasst von Ji Hye Heo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hallym University College of Medicine, 1 Hallymdaehak-gil, Chuncheon, 24252, Republic of Korea. Electronic address: …. Hauptthemen laut MEDLINE: Liver Cirrhosis, Cardiovascular Diseases, Metabolic Syndrome, Kidney Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: Cardiovascular-kidney-metabolic (CKM) syndrome reflects systemic cardiometabolic risk, but whether hepatic steatosis or fibrosis provides incremental prognostic information beyond CKM staging remains unclear. We evaluated the prognostic contributions of steatosis- and fibrosis-based hepatic phenotypes across CKM stages. METHODS AND RESULTS: This prospective cohort study included 602,885 adults undergoing health screening between 2005 and 2022 in the Kangbuk Samsung Health Study. CKM stage was classified according to the 2023 American Heart Association criteria. Hepatic steatosis was assessed using ultrasonography-defined fatty liver and metabolic dysfunction-associated steatotic liver disease, whereas hepatic fibrosis was assessed using the fibrosis-4 (FIB-4) index. During a median follow-up of 7.4 years, advancing CKM stage was associated with progressively higher risks of all-cause, cardiovascular, and liver-related mortality. Compared with CKM stage 0, CKM stage 3 was associated with increased risks of all-cause mortality (hazard ratio [HR], 2.10; 95% confidence interval [CI], 1.82-2.42) and cardiovascular mortality (HR, 3.28; 95% CI, 2.20-4.88), while CKM stage 4 showed the highest cardiovascular mortality risk (HR, 4.69; 95% CI, 3.03-7.26). These associations remained robust after adjustment for hepatic phenotypes. Adding steatosis-based phenotypes produced minimal improvement in risk discrimination beyond CKM staging. In contrast, adding FIB-4 improved prediction of liver-related mortality, increasing the C statistic from 0.8672 to 0.8972 with a categorical net reclassification improvement of 0.610 (95% CI, 0.556-0.665). CONCLUSIONS: CKM staging captured most systemic cardiometabolic mortality risk, whereas hepatic fibrosis, but not steatosis, provided additional prognostic information for liver-related mortality.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisCardiovascular DiseasesMetabolic SyndromeKidney DiseasesFatty LiverNon-alcoholic Fatty Liver DiseaseHumansMaleFemaleProspective StudiesMiddle AgedPrognosisRisk AssessmentPredictive Value of TestsTime FactorsAgedAdultRepublic of KoreaPhenotypeCardiometabolic Risk FactorsRisk FactorsSeverity of Illness Index

Stichwörter der Autor:innen

Cardiovascular-kidney-metabolic syndromeLiver fibrosisMASLDMortalityRisk stratificationSteatosis

Autor:innen und Institutionen

  • Department of Internal Medicine, Hallym University College of Medicine, 1 Hallymdaehak-gil, Chuncheon, 24252, Republic of Korea. Electronic address: jihyeheo02@gmail.com.
  • Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 04514, Republic of Korea; Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul…
  • MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, 06351, Republic of Korea. Electronic address: kcmd.sung@samsung.com.

Zitieren

APA

Heo, J. H., Sung, D. E., Kang, J., Zhou, X. D., Zheng, M. H., & Sung, K. C. (2026). Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging. Nutrition, Metabolism and Cardiovascular Diseases. https://doi.org/10.1016/j.numecd.2026.104817

Vancouver

Heo JH, Sung DE, Kang J, Zhou XD, Zheng MH, Sung KC. Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging. Nutrition, Metabolism and Cardiovascular Diseases. 2026. doi:10.1016/j.numecd.2026.104817

BibTeX
@article{Heo2026,
  author = {Heo, Ji Hye and Sung, Da-Eun and Kang, Jeonggyu and Zhou, Xiao-Dong and Zheng, Ming-Hua and Sung, Ki-Chul},
  title = {Liver fibrosis, but not steatosis, provides incremental prognostic value beyond cardiovascular-kidney-metabolic staging},
  journal = {Nutrition, Metabolism and Cardiovascular Diseases},
  year = {2026},
  doi = {10.1016/j.numecd.2026.104817}
}
Kostenlos starten →